The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD.
Parikh SA, et al. Among authors: kay ne.
Cancer Med. 2020 May;9(10):3390-3399. doi: 10.1002/cam4.2998. Epub 2020 Mar 18.
Cancer Med. 2020.
PMID: 32187452
Free PMC article.